Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.

Ozaki Y, Imanishi T, Tanimoto T, Kashiwagi M, Tsujioka H, Sougawa H, Orii M, Shiono Y, Shimamura K, Ishibashi K, Komukai K, Ino Y, Kitabata H, Akasaka T.

Circ J. 2012;76(6):1461-8.

2.

Effect of direct renin inhibitor on left ventricular remodeling in patients with primary acute myocardial infarction.

Ozaki Y, Imanishi T, Tanimoto T, Teraguchi I, Nishiguchi T, Orii M, Shiono Y, Shimamura K, Yamano T, Ino Y, Yamaguchi T, Kubo T, Akasaka T.

Int Heart J. 2014;55(1):17-21.

3.

Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.

Yano H, Hibi K, Nozawa N, Ozaki H, Kusama I, Ebina T, Kosuge M, Tsukahara K, Okuda J, Morita S, Umemura S, Kimura K.

Circ J. 2012;76(6):1442-51.

4.

Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction.

Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T, Kitabata H, Okochi K, Arita Y, Ishibashi K, Komukai K, Kataiwa H, Nakamura N, Hirata K, Tanaka A, Akasaka T.

J Am Coll Cardiol. 2009 Jul 7;54(2):130-8. doi: 10.1016/j.jacc.2009.04.021.

5.

Does direct inhibition bring direct benefit?

Abe S, Taguchi I, Inoue T.

Circ J. 2012;76(6):1326. No abstract available.

6.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721.

7.

Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.

Bomback AS, Toto R.

Am J Hypertens. 2009 Oct;22(10):1032-40. doi: 10.1038/ajh.2009.138. Review.

PMID:
19661925
8.

Aliskiren and valsartan combination therapy for the management of hypertension.

Epstein BJ.

Vasc Health Risk Manag. 2010 Sep 7;6:711-22. Review.

9.

Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.

Doulton TW, MacGregor GA.

J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):185-9. doi: 10.1177/1470320309342733.

PMID:
19617273
10.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
11.

Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists.

Ito T, Ishikawa E, Fujimoto N, Okubo S, Ito G, Ichikawa T, Nomura S, Ito M.

Clin Exp Hypertens. 2014;36(7):497-502. doi: 10.3109/10641963.2013.863323.

PMID:
24433061
12.
13.

[The future of renin inhibition].

Uresin AY, Baran E.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:32-8. Turkish.

14.

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A.

Expert Opin Pharmacother. 2007 Apr;8(5):529-35. Review.

PMID:
17376010
16.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 .

PMID:
18307835
17.

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J; ATMOSPHERE Investigators..

Eur J Heart Fail. 2011 Jan;13(1):107-14. doi: 10.1093/eurjhf/hfq212.

18.

Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context.

Krum H, Maggioni A.

Clin Cardiol. 2010 Sep;33(9):536-41. doi: 10.1002/clc.20828. Review.

19.

Recent changes in the landscape of combination RAS blockade.

Epstein BJ, Smith SM, Choksi R.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127. Review.

PMID:
19900020
20.

ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.

Düsing R, Sellers F.

Curr Med Res Opin. 2009 Sep;25(9):2287-301. doi: 10.1185/03007990903152045. Review.

PMID:
19635044
Items per page

Supplemental Content

Support Center